Armata Pharmaceuticals, Inc. (ARMP)
NYSEAMERICAN: ARMP · Real-Time Price · USD
8.20
-0.62 (-7.03%)
At close: May 14, 2026, 4:00 PM EDT
8.00
-0.20 (-2.44%)
After-hours: May 14, 2026, 4:53 PM EDT
Armata Pharmaceuticals Revenue
Armata Pharmaceuticals had revenue of $789.00K in the quarter ending March 31, 2026, with 60.69% growth. This brings the company's revenue in the last twelve months to $5.20M, up 10.70% year-over-year. In the year 2025, Armata Pharmaceuticals had annual revenue of $4.90M, down -5.22%.
Revenue (ttm)
$5.20M
Revenue Growth
+10.70%
P/S Ratio
60.38
Revenue / Employee
$86,700
Employees
60
Market Cap
300.90M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.90M | -270.00K | -5.22% |
| Dec 31, 2024 | 5.17M | 645.00K | 14.24% |
| Dec 31, 2023 | 4.53M | -979.00K | -17.77% |
| Dec 31, 2022 | 5.51M | 1.03M | 23.11% |
| Dec 31, 2021 | 4.47M | 3.65M | 443.62% |
| Dec 31, 2020 | 823.00K | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | 115.00K | -145.00K | -55.77% |
| Dec 31, 2016 | 260.00K | -215.00K | -45.26% |
| Dec 31, 2015 | 475.00K | 66.00K | 16.14% |
| Dec 31, 2014 | 409.00K | 328.00K | 404.94% |
| Dec 31, 2013 | 81.00K | -583.00K | -87.80% |
| Dec 31, 2012 | 664.00K | -8.05M | -92.38% |
| Dec 31, 2008 | 8.72M | -1.61M | -15.62% |
| Dec 31, 2007 | 10.33M | 468.00K | 4.74% |
| Dec 31, 2006 | 9.86M | 2.99M | 43.50% |
| Dec 31, 2005 | 6.87M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bicycle Therapeutics | 63.50M |
| Zentalis Pharmaceuticals | 26.87M |
| Lineage Cell Therapeutics | 14.78M |
| Abeona Therapeutics | 14.54M |
| Silence Therapeutics | 839.00K |
| Inhibikase Therapeutics | 1.00 |
ARMP News
- 1 day ago - Armata Pharmaceuticals reports Q1 EPS ($3.16) vs. (20c) last year - TheFly
- 1 day ago - Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update - PRNewsWire
- 7 days ago - Armata Pharmaceuticals secures FDA Fast Track Designation for AP-SA02 - TheFly
- 7 days ago - Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02 - PRNewsWire
- 10 days ago - Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology" - PRNewsWire
- 17 days ago - Armata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D. - PRNewsWire
- 5 weeks ago - Armata Pharmaceuticals price target raised to $20 from $15 at JonesResearch - TheFly
- 7 weeks ago - Armata Pharmaceuticals reports Q4 EPS ($3.42) vs. (23c) last year - TheFly